SeekingAlpha · Sep 17, 2026
Summit Therapeutics: It's Okay Not To Have An Answer
Summit Therapeutics' ivonescimab data looks promising but uncertain amid dilution, royalties and catalysts. See why I rate SMMT stock a Hold right now.
SM
NASDAQ · SMMT
Summit Therapeutics Inc.
Healthcare · Biotechnology
$17.85
Up+$0.13 (+0.73%)
Updated Sep 20, 2026, 12:13 PM
SID Score
5.7/10
Composite research score
Smart Money
61/100
Neutral
- Market cap
- 13.39B
- P/E ratio
- -14.51
- Dividend yield
- 0.00%
- 52-week range
- $12.07 – $29.23
- Volume
- 13.06M
- Avg. volume
- 3.43M
Price performance
SMMT price history
1M range · 19 trading sessions · Daily adjusted prices
SMMT closed at $17.85 after 19 trading sessions, up 40.22% for the selected period.
- Last close
- $17.85
- Period change
- +40.22%
- Period low
- $12.73
- Period high
- $18.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $17.735 | $17.87 | $17.31 | $17.85 | 13.06M |
| Sep 17, 2026 | $17.73 | $18.10 | $17.42 | $17.72 | 6.13M |
| Sep 16, 2026 | $17.50 | $17.75 | $17.11 | $17.30 | 6.09M |
| Sep 15, 2026 | $18.16 | $18.47 | $17.11 | $17.40 | 5.8M |
| Sep 14, 2026 | $18.07 | $18.83 | $17.97 | $18.42 | 7.07M |
| Sep 11, 2026 | $17.20 | $17.70 | $17.1375 | $17.55 | 4.28M |
| Sep 10, 2026 | $17.30 | $17.6208 | $16.80 | $17.00 | 4.22M |
| Sep 9, 2026 | $18.205 | $18.3216 | $17.24 | $17.54 | 4.8M |
| Sep 8, 2026 | $17.43 | $17.69 | $16.967 | $17.28 | 7.36M |
| Sep 4, 2026 | $16.935 | $17.63 | $16.80 | $17.605 | 6.95M |
| Sep 3, 2026 | $15.52 | $17.35 | $15.515 | $17.13 | 14.92M |
| Sep 2, 2026 | $14.15 | $14.72 | $14.06 | $14.60 | 3.78M |
| Sep 1, 2026 | $13.38 | $14.475 | $13.37 | $14.16 | 4.7M |
| Aug 31, 2026 | $13.51 | $13.73 | $13.44 | $13.62 | 5.43M |
| Aug 28, 2026 | $14.11 | $14.24 | $13.43 | $13.73 | 3.91M |
| Aug 27, 2026 | $14.30 | $14.65 | $13.92 | $14.33 | 4.84M |
| Aug 26, 2026 | $14.75 | $15.10 | $14.1137 | $14.23 | 11.63M |
| Aug 25, 2026 | $13.27 | $13.60 | $13.05 | $13.36 | 6.33M |
| Aug 24, 2026 | $13.08 | $13.21 | $12.22 | $12.73 | 4.39M |
Latest SMMT news
The latest Smart Investors Daily articles mentioning SMMT.
Stock researchCompany · Overview
SMMT research
Overview
Company profile and research snapshot.
Company profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Jefferies | Buy | — |
| Aug 26, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 25, 2026 | Bernstein | Market Perform | — |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 12, 2026 | Leerink Partners | Market Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 16, 2026
Is Summit Therapeutics (SMMT) Below Fair Value On New Ivonescimab Survival Data?
Summit Therapeutics (SMMT) is back in focus after presenting new Phase III ivonescimab data in non small cell lung cancer, including updated overall survival and safety results, at the IASLC 2026 World Conference on Lung Cancer. Those fresh ivonescimab updates land after a sharp run, with Summit Therapeutics’ 30 day share price return of 30.34% and 90 day gain of 23.67% contrasting with a slightly negative year to date move. At the same time, the 3 year total shareholder return above 8x hints...
Yahoo · Sep 15, 2026
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
MIAMI, September 15, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea.
Benzinga · Sep 15, 2026
Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
